ALK in Lung Cancer: Past, Present, and Future

被引：381

作者：

Shaw, Alice T. ^{[1
,2
]}

Engelman, Jeffrey A. ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[2] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 08期

关键词：

ANAPLASTIC LYMPHOMA KINASE; EML4-ALK FUSION GENE; EGFR MUTATION; 1ST-LINE TREATMENT; OPEN-LABEL; RESISTANCE; CHEMOTHERAPY; CRIZOTINIB; GEFITINIB; ERLOTINIB;

D O I：

10.1200/JCO.2012.44.5353

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

In 2007, scientists discovered that anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non-small-cell lung cancers. ALK-positive cancers are highly sensitive to small-molecule ALK kinase inhibitors, such as crizotinib. Phase I and II studies of crizotinib in ALK-positive lung cancer demonstrated impressive activity and clinical benefit, leading to rapid US Food and Drug Administration approval in 2011. Although crizotinib induces remissions and extends the lives of patients, cures are not achieved as resistance to therapy develops. In this review, we will discuss the history of this field, current diagnostic and treatment practices, and future challenges and opportunities to advance outcomes for patients with ALK-positive lung cancers. J Clin Oncol 31:1105-1111. (C) 2013 by American Society of Clinical Oncology

引用

页码：1105 / 1111

页数：7

共 45 条

[1]

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers [J].

Bergethon, Kristin ;

Shaw, Alice T. ;

Ou, Sai-Hong Ignatius ;

Katayama, Ryohei ;

Lovly, Christine M. ;

McDonald, Nerina T. ;

Massion, Pierre P. ;

Siwak-Tapp, Christina ;

Gonzalez, Adriana ;

Fang, Rong ;

Mark, Eugene J. ;

Batten, Julie M. ;

Chen, Haiquan ;

Wilner, Keith D. ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Carbone, David P. ;

Ji, Hongbin ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari ;

Pao, William ;

Iafrate, A. John .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) :863-870

[2]

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed [J].

Camidge, D. Ross ;

Kono, Scott A. ;

Lu, Xian ;

Okuyama, Sonia ;

Baron, Anna E. ;

Oton, Ana B. ;

Davies, Angela M. ;

Varella-Garcia, Marileila ;

Franklin, Wilbur ;

Doebele, Robert C. .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (04) :774-780

[3]

Camidge DR, 2011, J CLIN ONCOL, V29, p165s

[4]

Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene [J].

Chen, Zhao ;

Sasaki, Takaaki ;

Tan, Xiaohong ;

Carretero, Julian ;

Shimamura, Takeshi ;

Li, Danan ;

Xu, Chunxiao ;

Wang, Yuchuan ;

Adelmant, Guillaume O. ;

Capelletti, Marzia ;

Lee, Hyun Joo ;

Rodig, Scott J. ;

Borgman, Christa ;

Park, Seung-il ;

Kim, Hyeong Ryul ;

Padera, Robert ;

Marto, Jarrod A. ;

Gray, Nathanael S. ;

Kung, Andrew L. ;

Shapiro, Geoffrey I. ;

Jaenne, Pasi A. ;

Wong, Kwok-Kin .

CANCER RESEARCH, 2010, 70 (23) :9827-9836

[5]

The anaplastic lymphoma kinase in the pathogenesis of cancer [J].

Chiarle, Roberto ;

Voena, Claudia ;

Ambrogio, Chiara ;

Piva, Roberto ;

Inghirami, Giorgio .

NATURE REVIEWS CANCER, 2008, 8 (01) :11-23

[6]

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors [J].

Choi, Young Lim ;

Soda, Manabu ;

Yamashita, Yoshihiro ;

Ueno, Toshihide ;

Takashima, Junpei ;

Nakajima, Takahiro ;

Yatabe, Yasushi ;

Takeuchi, Kengo ;

Hamada, Toru ;

Haruta, Hidenori ;

Ishikawa, Yuichi ;

Kimura, Hideki ;

Mitsudomi, Tetsuya ;

Tanio, Yoshiro ;

Mano, Hiroyuki .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1734-1739

[7]

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) [J].

Cui, J. Jean ;

Tran-Dube, Michelle ;

Shen, Hong ;

Nambu, Mitchell ;

Kung, Pei-Pei ;

Pairish, Mason ;

Jia, Lei ;

Meng, Jerry ;

Funk, Lee ;

Botrous, Iriny ;

McTigue, Michele ;

Grodsky, Neil ;

Ryan, Kevin ;

Padrique, Ellen ;

Alton, Gordon ;

Timofeevski, Sergei ;

Yamazaki, Shinji ;

Li, Quhua ;

Zou, Helen ;

Christensen, James ;

Mroczkowski, Barbara ;

Bender, Steve ;

Kania, Robert S. ;

Edwards, Martin P. .

JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (18) :6342-6363

[8]

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine [J].

Dias-Santagata, Dora ;

Akhavanfard, Sara ;

David, Serena S. ;

Vernovsky, Kathy ;

Kuhlmann, Georgiana ;

Boisvert, Susan L. ;

Stubbs, Hannah ;

McDermott, Ultan ;

Settleman, Jeffrey ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Isakoff, Steven J. ;

Sequist, Lecia V. ;

Engelman, Jeffrey A. ;

Lynch, Thomas J. ;

Haber, Daniel A. ;

Louis, David N. ;

Ellisen, Leif W. ;

Borger, Darrell R. ;

Lafrate, A. John .

EMBO MOLECULAR MEDICINE, 2010, 2 (05) :146-158

[9]

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer [J].

Doebele, Robert C. ;

Pilling, Amanda B. ;

Aisner, Dara L. ;

Kutateladze, Tatiana G. ;

Le, Anh T. ;

Weickhardt, Andrew J. ;

Kondo, Kimi L. ;

Linderman, Derek J. ;

Heasley, Lynn E. ;

Franklin, Wilbur A. ;

Varella-Garcia, Marileila ;

Camidge, D. Ross .

CLINICAL CANCER RESEARCH, 2012, 18 (05) :1472-1482

[10]

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Mitsudomi, Tetsuya ;

Song, Youngchul ;

Hyland, Courtney ;

Park, Joon Oh ;

Lindeman, Neal ;

Gale, Christopher-Michael ;

Zhao, Xiaojun ;

Christensen, James ;

Kosaka, Takayuki ;

Holmes, Alison J. ;

Rogers, Andrew M. ;

Cappuzzo, Federico ;

Mok, Tony ;

Lee, Charles ;

Johnson, Bruce E. ;

Cantley, Lewis C. ;

Janne, Pasi A. .

SCIENCE, 2007, 316 (5827) :1039-1043

← 1 2 3 4 5 →